JP2017093436A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017093436A5 JP2017093436A5 JP2016232150A JP2016232150A JP2017093436A5 JP 2017093436 A5 JP2017093436 A5 JP 2017093436A5 JP 2016232150 A JP2016232150 A JP 2016232150A JP 2016232150 A JP2016232150 A JP 2016232150A JP 2017093436 A5 JP2017093436 A5 JP 2017093436A5
- Authority
- JP
- Japan
- Prior art keywords
- lipid
- nucleic acid
- water
- lipid component
- ratio
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims 21
- 150000002632 lipids Chemical class 0.000 claims 15
- 108020004707 nucleic acids Proteins 0.000 claims 10
- 150000007523 nucleic acids Chemical class 0.000 claims 10
- 102000039446 nucleic acids Human genes 0.000 claims 10
- -1 cationic lipid Chemical class 0.000 claims 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 6
- 239000003960 organic solvent Substances 0.000 claims 4
- 229920000768 polyamine Polymers 0.000 claims 4
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 claims 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 3
- 239000002502 liposome Substances 0.000 claims 3
- 230000007935 neutral effect Effects 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 3
- 125000002091 cationic group Chemical group 0.000 claims 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 claims 2
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 claims 2
- 229940063675 spermine Drugs 0.000 claims 2
- SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 claims 1
- KSXTUUUQYQYKCR-LQDDAWAPSA-M 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KSXTUUUQYQYKCR-LQDDAWAPSA-M 0.000 claims 1
- XULFJDKZVHTRLG-JDVCJPALSA-N DOSPA trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F.CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)CCNC(=O)C(CCCNCCCN)NCCCN)OCCCCCCCC\C=C/CCCCCCCC XULFJDKZVHTRLG-JDVCJPALSA-N 0.000 claims 1
- 239000005700 Putrescine Substances 0.000 claims 1
- 108091027967 Small hairpin RNA Proteins 0.000 claims 1
- 108020004459 Small interfering RNA Proteins 0.000 claims 1
- 235000012000 cholesterol Nutrition 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 150000003904 phospholipids Chemical class 0.000 claims 1
- 239000004055 small Interfering RNA Substances 0.000 claims 1
- 229940063673 spermidine Drugs 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161443246P | 2011-02-15 | 2011-02-15 | |
| US61/443,246 | 2011-02-15 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013553671A Division JP6054308B2 (ja) | 2011-02-15 | 2012-02-15 | 核酸を細胞へ送達する組成物及び方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017093436A JP2017093436A (ja) | 2017-06-01 |
| JP2017093436A5 true JP2017093436A5 (https=) | 2017-09-14 |
| JP6313406B2 JP6313406B2 (ja) | 2018-04-18 |
Family
ID=46673165
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013553671A Expired - Fee Related JP6054308B2 (ja) | 2011-02-15 | 2012-02-15 | 核酸を細胞へ送達する組成物及び方法 |
| JP2016232150A Active JP6313406B2 (ja) | 2011-02-15 | 2016-11-30 | 核酸を細胞へ送達する組成物及び方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013553671A Expired - Fee Related JP6054308B2 (ja) | 2011-02-15 | 2012-02-15 | 核酸を細胞へ送達する組成物及び方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US20140065204A1 (https=) |
| EP (1) | EP2675918B1 (https=) |
| JP (2) | JP6054308B2 (https=) |
| AU (1) | AU2012217685B2 (https=) |
| CA (1) | CA2827118A1 (https=) |
| WO (1) | WO2012112730A2 (https=) |
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012019168A2 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| RU2013120302A (ru) | 2010-10-01 | 2014-11-20 | Модерна Терапьютикс, Инк. | Сконструированные нуклеиновые кислоты и способы их применения |
| EP2691101A2 (en) | 2011-03-31 | 2014-02-05 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| RU2648950C2 (ru) | 2011-10-03 | 2018-04-02 | Модерна Терапьютикс, Инк. | Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение |
| CN104114572A (zh) | 2011-12-16 | 2014-10-22 | 现代治疗公司 | 经修饰的核苷、核苷酸和核酸组合物 |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| AU2013243948A1 (en) | 2012-04-02 | 2014-10-30 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins associated with human disease |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| US9254311B2 (en) | 2012-04-02 | 2016-02-09 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins |
| AU2013202947B2 (en) | 2012-06-13 | 2016-06-02 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
| US9717724B2 (en) | 2012-06-13 | 2017-08-01 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies |
| ITRM20120480A1 (it) * | 2012-10-09 | 2014-04-10 | Uni Degli Studi Camerino | Nanoparticelle lipidiche multicomponenti e procedimenti per la loro preparazione. |
| WO2014081507A1 (en) | 2012-11-26 | 2014-05-30 | Moderna Therapeutics, Inc. | Terminally modified rna |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| US10023626B2 (en) | 2013-09-30 | 2018-07-17 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
| JP2016538829A (ja) | 2013-10-03 | 2016-12-15 | モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | 低密度リポタンパク質受容体をコードするポリヌクレオチド |
| SG10201912038TA (en) | 2014-04-23 | 2020-02-27 | Modernatx Inc | Nucleic acid vaccines |
| WO2016007644A1 (en) | 2014-07-08 | 2016-01-14 | The Children's Medical Center Corporation | Compositions and methods for treating diabetes |
| US11318131B2 (en) | 2015-05-18 | 2022-05-03 | Ipsen Biopharm Ltd. | Nanoliposomal irinotecan for use in treating small cell lung cancer |
| WO2016191547A1 (en) * | 2015-05-26 | 2016-12-01 | Comfort Care For Animals Llc | Liposome loading |
| EP3337467B1 (en) | 2015-08-20 | 2020-12-09 | Ipsen Biopharm Ltd. | Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment |
| MX385425B (es) | 2015-08-21 | 2025-03-18 | Ipsen Biopharm Ltd | Irinotecán liposomal y oxaliplatino, 5-fluoroacilo y leucovorina para usarse en el tratamiento de cáncer pancreático metastásico. |
| EP4286012A3 (en) | 2015-09-17 | 2024-05-29 | ModernaTX, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
| CN108291227A (zh) | 2015-10-14 | 2018-07-17 | 拜奥-帕斯控股股份有限公司 | 用于脂质体制剂的对乙氧基核酸 |
| MX382522B (es) | 2015-10-16 | 2025-03-13 | Ipsen Biopharm Ltd | Composiciones farmaceuticas estabilizantes de camptotecina. |
| HRP20220652T1 (hr) | 2015-12-10 | 2022-06-24 | Modernatx, Inc. | Pripravci i postupci unosa terapijskih sredstava |
| HUE057877T2 (hu) | 2015-12-22 | 2022-06-28 | Modernatx Inc | Vegyületek és készítmények terápiás szerek intracelluláris bejuttatására |
| AU2017325971A1 (en) | 2016-09-16 | 2019-04-11 | Bio-Path Holdings, Inc. | Combination therapy with liposomal antisense oligonucleotides |
| EP3535026A1 (en) | 2016-11-02 | 2019-09-11 | Ipsen Biopharm Limited | Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluoruracil (and leucovorin) |
| US11583504B2 (en) | 2016-11-08 | 2023-02-21 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
| WO2018170322A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Crystal forms of amino lipids |
| SMT202300097T1 (it) | 2017-03-15 | 2023-05-12 | Modernatx Inc | Composto e composizioni per il rilascio intracellulare di agenti terapeutici |
| US11969506B2 (en) | 2017-03-15 | 2024-04-30 | Modernatx, Inc. | Lipid nanoparticle formulation |
| KR102723213B1 (ko) * | 2017-03-29 | 2024-10-30 | 인스티튜트 오브 베이직 메디컬 사이언시즈, 차이니즈 아카데미 오브 메디컬 사이언시즈 | 핵산 전달제 및 그의 관련 제품의 제조에 있어서의 화합물 또는 전통 중국 의약 추출물의 적용 |
| EA201992485A1 (ru) | 2017-04-19 | 2020-02-17 | Байо-Пат Холдингз, Инк. | Р-этокси нуклеиновые кислоты для ингибирования stat3 |
| EA201992490A1 (ru) | 2017-04-19 | 2020-03-03 | Байо-Пат Холдингз, Инк. | Р-этокси нуклеиновые кислоты для ингибирования bcl2 |
| US12077501B2 (en) | 2017-06-14 | 2024-09-03 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of agents |
| WO2019046809A1 (en) | 2017-08-31 | 2019-03-07 | Modernatx, Inc. | METHODS OF MANUFACTURING LIPID NANOPARTICLES |
| JP6462073B1 (ja) * | 2017-09-04 | 2019-01-30 | 一丸ファルコス株式会社 | ｐＨ感受性リポソームの製造方法 |
| TW201927288A (zh) | 2017-10-20 | 2019-07-16 | 德商拜恩迪克Ｒｎａ製藥有限公司 | 適用於治療之微脂體ｒｎａ配製物的製備及儲存 |
| US12280114B2 (en) | 2018-03-29 | 2025-04-22 | Institute Of Basic Medical Sciences | Extraction of plant source “medicinal soup” and manual preparation of “herbal medicine” and related products |
| EP3778556A4 (en) * | 2018-03-29 | 2022-04-20 | Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences | APPLICATION OF A TRADITIONAL CHINESE MEDICINE COMPOUND OR EXTRACT IN THE MANUFACTURE OF A NUCLEIC ACID RELEASE AGENT AND RELATED PRODUCTS |
| AU2019345067A1 (en) | 2018-09-19 | 2021-04-08 | Modernatx, Inc. | High-purity peg lipids and uses thereof |
| MA53650A (fr) | 2018-09-19 | 2021-07-28 | Modernatx Inc | Lipides peg et leurs utilisations |
| US12263248B2 (en) | 2018-09-19 | 2025-04-01 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
| CN113271926A (zh) | 2018-09-20 | 2021-08-17 | 摩登纳特斯有限公司 | 脂质纳米颗粒的制备及其施用方法 |
| US11197827B2 (en) * | 2018-10-31 | 2021-12-14 | Microsoft Technology Licensing, Llc | Polynucleotide encapsulation and preservation using self-assembling membranes |
| WO2020200472A1 (en) * | 2019-04-05 | 2020-10-08 | Biontech Rna Pharmaceuticals Gmbh | Preparation and storage of liposomal rna formulations suitable for therapy |
| AU2020350759A1 (en) | 2019-09-19 | 2022-03-31 | Modernatx, Inc. | Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents |
| BR112022004936A2 (pt) | 2019-09-19 | 2022-06-14 | Modernatx Inc | Compostos lipídicos contendo carbonato e composições para distribuição intracelular de agentes terapêuticos |
| US20230372397A1 (en) | 2020-10-06 | 2023-11-23 | Iovance Biotherapeutics, Inc. | Treatment of nsclc patients with tumor infiltrating lymphocyte therapies |
| WO2022076606A1 (en) | 2020-10-06 | 2022-04-14 | Iovance Biotherapeutics, Inc. | Treatment of nsclc patients with tumor infiltrating lymphocyte therapies |
| US20240123067A1 (en) | 2020-12-17 | 2024-04-18 | Iovance Biotherapeutics, Inc. | Treatment of cancers with tumor infiltrating lymphocyte therapies |
| CA3202483A1 (en) | 2020-12-17 | 2022-06-23 | Maria Fardis | Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors |
| US11524023B2 (en) | 2021-02-19 | 2022-12-13 | Modernatx, Inc. | Lipid nanoparticle compositions and methods of formulating the same |
| EP4326287A2 (en) | 2021-04-19 | 2024-02-28 | Iovance Biotherapeutics, Inc. | Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies |
| US20240342285A1 (en) | 2021-07-28 | 2024-10-17 | Iovance Biotherapeutics, Inc. | Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with kras inhibitors |
| WO2023077015A2 (en) | 2021-10-27 | 2023-05-04 | Iovance Biotherapeutics, Inc. | Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy |
| EP4430167A1 (en) | 2021-11-10 | 2024-09-18 | Iovance Biotherapeutics, Inc. | Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes |
| CA3248034A1 (en) | 2022-04-15 | 2023-10-19 | Iovance Biotherapeutics, Inc. | METHODS FOR EXPANSION OF TIL CELLS BY MEANS OF SPECIFIC CYTOKINE COMBINATIONS AND/OR AKT INHIBITOR TREATMENT |
| CN114984236B (zh) * | 2022-04-29 | 2023-03-24 | 深圳近邻生物科技有限公司 | 一种响应型核酸递送系统及其制备方法、交联聚合物载体 |
| WO2025108545A1 (en) * | 2023-11-22 | 2025-05-30 | Danmarks Tekniske Universitet | Delivery of nucleotides from injectable biomaterial |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5908635A (en) * | 1994-08-05 | 1999-06-01 | The United States Of America As Represented By The Department Of Health And Human Services | Method for the liposomal delivery of nucleic acids |
| US5885613A (en) | 1994-09-30 | 1999-03-23 | The University Of British Columbia | Bilayer stabilizing components and their use in forming programmable fusogenic liposomes |
| US6214388B1 (en) | 1994-11-09 | 2001-04-10 | The Regents Of The University Of California | Immunoliposomes that optimize internalization into target cells |
| US6210707B1 (en) | 1996-11-12 | 2001-04-03 | The Regents Of The University Of California | Methods of forming protein-linked lipidic microparticles, and compositions thereof |
| US7244826B1 (en) | 1998-04-24 | 2007-07-17 | The Regents Of The University Of California | Internalizing ERB2 antibodies |
| US6794128B2 (en) | 1998-04-24 | 2004-09-21 | The Regents Of The University Of California | Methods of selecting internalizing antibodies |
| US7780882B2 (en) * | 1999-02-22 | 2010-08-24 | Georgetown University | Simplified and improved method for preparing an antibody or an antibody fragment targeted immunoliposome for systemic administration of a therapeutic or diagnostic agent |
| DE602004027655D1 (de) * | 2003-11-03 | 2010-07-22 | Yissum Res Dev Co | Verfahren zur auswahl von kationischen oder anionischen liposomen zur behandlung einer schleimhautmembran und diese enthaltendes set |
| JP4651276B2 (ja) * | 2003-11-12 | 2011-03-16 | テルモ株式会社 | リポソームを体内より排泄する抗体およびリポソームの血中クリアランス促進剤 |
| JP3941808B2 (ja) | 2004-10-28 | 2007-07-04 | 株式会社日立製作所 | 動画像の変化点検出方法及び装置 |
| US20070171077A1 (en) | 2006-01-26 | 2007-07-26 | Behrouz Kawarizadeh | License Plate Incorporating RFID Device |
| WO2008096779A1 (ja) * | 2007-02-09 | 2008-08-14 | National University Corporation NARA Institute of Science and Technology | Ｃ７０含有リポソームおよびその製造方法、並びにその利用 |
| SG178789A1 (en) | 2007-02-16 | 2012-03-29 | Merrimack Pharmaceuticals Inc | Antibodies against erbb3 and uses thereof |
| CA2702103A1 (en) | 2007-10-12 | 2009-04-16 | Novosom Ag | Improvements in or relating to amphotaric liposomes comprising neutral lipids |
| WO2009061515A1 (en) * | 2007-11-09 | 2009-05-14 | Northeastern University | Self-assembling micelle-like nanoparticles for systemic gene delivery |
| CN102231979B (zh) * | 2008-10-16 | 2014-10-29 | 玛瑞纳生物技术有限公司 | 基因沉默治疗剂的脂质体有效递送方法和组合物 |
| JP5532635B2 (ja) * | 2009-03-11 | 2014-06-25 | 凸版印刷株式会社 | 核酸含有リポソームを用いた遺伝子解析方法及び遺伝子解析キット |
| EP2453911A1 (en) | 2009-04-30 | 2012-05-23 | Genetic Immunity Kft | Immunogenic nanomedicine composition and preparation and uses thereof |
| US8420118B2 (en) * | 2009-09-10 | 2013-04-16 | The Board Of Regents Of The University Of Oklahoma | Anionic lipids and lipid nano-structures and methods of producing and using same |
-
2012
- 2012-02-15 EP EP12746634.0A patent/EP2675918B1/en not_active Not-in-force
- 2012-02-15 AU AU2012217685A patent/AU2012217685B2/en not_active Ceased
- 2012-02-15 CA CA2827118A patent/CA2827118A1/en not_active Abandoned
- 2012-02-15 WO PCT/US2012/025324 patent/WO2012112730A2/en not_active Ceased
- 2012-02-15 JP JP2013553671A patent/JP6054308B2/ja not_active Expired - Fee Related
-
2013
- 2013-08-15 US US13/967,664 patent/US20140065204A1/en not_active Abandoned
-
2016
- 2016-01-22 US US15/004,481 patent/US10087464B2/en not_active Expired - Fee Related
- 2016-11-30 JP JP2016232150A patent/JP6313406B2/ja active Active
-
2018
- 2018-07-02 US US16/025,503 patent/US20190017073A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017093436A5 (https=) | ||
| JP7496808B2 (ja) | リポカチオン性デンドリマーおよびその使用 | |
| JP7480220B2 (ja) | カチオン性スルホンアミドアミノ脂質および両親媒性両性イオンアミノ脂質 | |
| Malhotra et al. | Glycine-terminated dendritic amphiphiles for nonviral gene delivery | |
| AU2016385135B2 (en) | Bifurcating mixers and methods of their use and manufacture | |
| Thomas et al. | Polyamine–DNA interactions and development of gene delivery vehicles | |
| JP6313406B2 (ja) | 核酸を細胞へ送達する組成物及び方法 | |
| CN105939699B (zh) | 脂质体颗粒、制备所述脂质体颗粒的方法以及其用途 | |
| JP2012526858A5 (https=) | ||
| CA2935914C (en) | Cationic lipid | |
| JP2010184947A5 (https=) | ||
| JP2019508371A5 (https=) | ||
| JP2009513151A5 (https=) | ||
| CA2748520A1 (en) | Pharmaceutical composition containing an anionic drug, and a production method therefor | |
| CN107028886A (zh) | 含有核酸的脂质粒子及相关的方法 | |
| CN108366964A (zh) | 制备含阴离子药物的聚合物胶束的方法 | |
| JP2012532839A5 (https=) | ||
| David et al. | siRNA LNCs–a novel platform of lipid nanocapsules for systemic siRNA administration | |
| WO2010142660A2 (en) | Drug delivery system | |
| EP2140870A1 (en) | Prompt nucleic acid delivery carrier composition | |
| Kocsis et al. | Supramolecular rulers enabling selective detection of pure short ssDNA via chiral self-assembly | |
| US20250319035A1 (en) | Cationic lipid nanoparticle having high transfection efficiency and preparation method therefor | |
| WO2025011380A1 (zh) | 脂质化合物、组合物及其制备方法和应用 | |
| JP5808246B2 (ja) | 核酸複合体、及び核酸送達用組成物 | |
| CN119913209A (zh) | 一种用于向细胞内递送核酸的组合物 |